Furthermore, PD-L1 expression—a key biomarker for ICI efficacy—appears to be upregulated in COPD-associated NSCLC, which may partly explain the improved response to ICIs observed in our meta-analysis [41, 42]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.